Reata Pharmaceuticals, Inc. RETA
Set alert
172.36 +172.36 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 4.04B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -22.49
- Beta
- 1.37
- Short ratio
- 5.10
- Inst. own
- 101.73%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 14, 2023
- 50-d avg
- 95.35
- 200-d avg
- 62.81
- 1y target
- 115.30
2Y chart
Events in this range
- Aug 8, 2022Earnings: —; estimate -1.9; surprise —%
- Nov 8, 2022Earnings: —; estimate -2.35; surprise —%
- Apr 3, 2023Earnings: —; estimate -2.21; surprise —%
- May 10, 2023Earnings: —; estimate -2.34; surprise —%
- May 11, 2023Rating: Barclays · Overweight → Overweight
- Jun 12, 2023Rating: SVB Leerink · Market Perform → Outperform
- Jun 28, 2023Rating: Barclays · Overweight → Overweight
- Jun 28, 2023Rating: Cantor Fitzgerald · Overweight → Overweight
- Jun 29, 2023Rating: Ladenburg Thalmann · Buy → Buy
- Jul 6, 2023Rating: TD Cowen · — → Outperform
- Aug 8, 2023Earnings: —; estimate -2.88; surprise —%
Signals (84)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Aug 16, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 28, 2023 | 3 years ago |
| RSI: Overbought | Jul 28, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 25, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 29, 2023 | 3 years ago |
| SMA: Bullish | Jun 28, 2023 | 3 years ago |
| SMA: Bearish | Jun 23, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 23, 2023 | 3 years ago |
| SMA: Bullish | Jun 21, 2023 | 3 years ago |
| SMA: Bearish | Jun 15, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | Jun 9, 2023 | 3 years ago |
| SMA: Bullish | Jun 8, 2023 | 3 years ago |
| SMA: Bearish | Jun 7, 2023 | 3 years ago |
| SMA: Bullish | Jun 6, 2023 | 3 years ago |
| MACD: Buy Signal | May 26, 2023 | 3 years ago |
| SMA: Bearish | May 25, 2023 | 3 years ago |
| SMA: Bullish | May 24, 2023 | 3 years ago |
| RSI: Oversold | May 18, 2023 | 3 years ago |
| SMA: Bearish | May 10, 2023 | 3 years ago |
| RSI: Overbought | May 5, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 22, 2023 | 3 years ago |
| SMA: Bullish | Mar 1, 2023 | 3 years ago |
| SMA: Bullish | Mar 1, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 1, 2023 | 3 years ago |
| RSI: Overbought | Mar 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 27, 2023 | 3 years ago |
| SMA: Bearish | Feb 27, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 10, 2023 | 3 years ago |
| RSI: Overbought | Feb 1, 2023 | 3 years ago |
| SMA: Bullish | Jan 12, 2023 | 3 years ago |
| SMA: Bearish | Jan 11, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Jan 4, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 4, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 3, 2023 | 3 years ago |
| SMA: Bullish | Dec 29, 2022 | 3 years ago |
| SMA: Bearish | Dec 23, 2022 | 3 years ago |
| SMA: Bullish | Dec 22, 2022 | 3 years ago |
| SMA: Bearish | Dec 21, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 17, 2022 | 3 years ago |
| RSI: Overbought | Nov 11, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 8, 2022 | 3 years ago |
| RSI: Overbought | Nov 8, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 28, 2022 | 4 years ago |
| RSI: Overbought | Oct 17, 2022 | 4 years ago |
| SMA: Bullish | Oct 14, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 14, 2022 | 4 years ago |
| SMA: Bullish | Oct 13, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 6, 2022 | 4 years ago |
| SMA: Bearish | Oct 4, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 3, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 22, 2022 | 4 years ago |
| SMA: Bearish | Sep 16, 2022 | 4 years ago |
| SMA: Bullish | Sep 14, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 24, 2022 | 4 years ago |
| RSI: Oversold | Aug 16, 2022 | 4 years ago |
| SMA: Bearish | Aug 8, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 8, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 4, 2022 | 4 years ago |
| SMA: Bullish | Aug 3, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 19, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 5, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 24, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 22, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 17, 2022 | 4 years ago |
| SMA: Bullish | Jun 15, 2022 | 4 years ago |
| SMA: Bearish | Jun 14, 2022 | 4 years ago |
| SMA: Bullish | Jun 3, 2022 | 4 years ago |
| MACD: Buy Signal | May 16, 2022 | 4 years ago |
| RSI: Oversold | May 9, 2022 | 4 years ago |
| SMA: Bearish | Apr 18, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 28, 2022 | 4 years ago |
| RSI: Overbought | Mar 22, 2022 | 4 years ago |
| RSI: Overbought | Mar 18, 2022 | 4 years ago |
| SMA: Bullish | Feb 28, 2022 | 4 years ago |
| RSI: Oversold | Jan 27, 2022 | 4 years ago |
| RSI: Oversold | Jan 21, 2022 | 4 years ago |
| RSI: Oversold | Jan 7, 2022 | 4 years ago |
| MACD: Buy Signal | Dec 27, 2021 | 4 years ago |
| RSI: Oversold | Dec 6, 2021 | 4 years ago |
Key statistics
- Market cap
- 4.04B
- Enterprise value
- 3.90B
- Trailing P/E
- 0.00
- Forward P/E
- -22.49
- PEG ratio
- 0.00
- Price / sales
- 2701.84
- Price / book
- 0.00
- EPS (TTM)
- -10.09
- Beta
- 1.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.50M
- Revenue growth
- -78.70%
- Free cash flow
- -143.59M
- Total cash
- 320.96M
- Total debt
- 117.93M
- Return on equity
- 0.00%
- Shares outstanding
- 33.04M
- Short % of float
- 16.35%
- 50-day average
- 95.35
- 200-day average
- 62.81
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 115.30 -33.1% downside
Now 172.36
- Target (low)
- 85.00
- Target (mean)
- 115.30
- Target (high)
- 140.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy6
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 14, 2023
Expected Nov 14, 2023. Consensus EPS estimate -2.88.
Financials — quick view
RETA Revenue — quarterly 22.75M
RETA Net income — quarterly 193.00M
RETA EPS — quarterly 5.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2023 | Sep 1, 2023 | -2.15 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | -2.88 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | -2.34 | — | — | — |
| Apr 3, 2023 | Dec 1, 2022 | -2.21 | — | — | — |
| Nov 8, 2022 | Sep 1, 2022 | -2.35 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -1.90 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 6, 2023 | TD Cowen | init | — | Outperform |
| Jun 29, 2023 | Ladenburg Thalmann | main | Buy | Buy |
| Jun 28, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jun 28, 2023 | Barclays | main | Overweight | Overweight |
| Jun 12, 2023 | SVB Leerink | up | Market Perform | Outperform |
| May 11, 2023 | Barclays | main | Overweight | Overweight |
About Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- reatapharma.com
News
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Your note
Sign in to keep a note on RETA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANAND BHASKAR | Officer | Sale | Jun 13, 2023 | 24,898 |
| BIR DAWN CARTER | Officer | Stock Award(Grant) | Jul 5, 2023 | 35,010 |
| EDWARDS MARTIN | Director | Stock Award(Grant) | Jun 6, 2023 | 6,116 |
| HUFF JAMES WARREN | Chief Executive Officer | Stock Award(Grant) | Jul 5, 2023 | 132,878 |
| MCCLELLAN WILLIAM D JR | Director | Stock Award(Grant) | Jun 6, 2023 | 6,017 |
| MEYER COLIN JOHN | Officer | Stock Award(Grant) | Jul 5, 2023 | 84,373 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| CPMG INC | 8.77% | 2,896,901 | 312.03M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 8.33% | 2,750,941 | 296.30M | Mar 30, 2023 |
| Blackrock Inc. | 6.69% | 2,209,749 | 238.01M | Mar 30, 2023 |
| Perceptive Advisors Llc | 6.57% | 2,169,276 | 233.65M | Mar 30, 2023 |
| First Light Asset Management, LLC | 4.80% | 1,586,928 | 170.93M | Mar 30, 2023 |
| Deutsche Bank Aktiengesellschaft | 4.52% | 1,494,877 | 161.01M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Specialized-Health Care Fund | 3.85% | 1,237,211 | 133.26M | Jan 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.56% | 822,629 | 88.61M | Dec 30, 2022 |
| Vanguard Small-Cap Index Fund | 2.16% | 694,862 | 74.84M | Dec 30, 2022 |
| iShares Russell 2000 ETF | 1.90% | 611,224 | 65.83M | Feb 27, 2023 |
| Vanguard Small Cap Value Index Fund | 1.52% | 486,866 | 52.44M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.20% | 383,789 | 41.34M | Dec 30, 2022 |